Better Leukemia Diagnostics Through AI (BELUGA)

Launched by MUNICH LEUKEMIA LABORATORY · Jul 9, 2020

Keywords

ClinConnect Summary

The BELUGA trial is studying how artificial intelligence (AI) can improve the diagnosis of blood cancers, including leukemia and lymphoma. Researchers are collecting a large number of blood samples to train an AI system that can analyze these samples and provide diagnostic information. This new method will be compared to the current best practices at a well-known lab to see if it can offer quicker and more accurate diagnoses for patients with suspected blood disorders.

To participate in this trial, individuals must be at least 18 years old and have been diagnosed with a suspected blood condition. The trial will only use samples that meet specific quality standards to ensure accurate results. If you join the study, you can expect that your sample will be analyzed using both traditional methods and the new AI technology. This research aims to improve how doctors diagnose blood cancers, which could lead to better treatment decisions for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients having been diagnosed with a suspected hematological disorder
• • The suspected diagnoses constitute a primary diagnosis
• • Only samples of patients min.18 years of age will be used
• • Samples must suffice quality attributes which are denoted in "Exclusion Criteria"
• Exclusion Criteria:
• • The sample is not fit for state-of-the-art diagnosis or fails initial quality control. For quality insurance, we will exclude samples in heparin- instead of EDTA. Samples with damage due to atmospheric reasons (freeze-thaw damage or elevated temperature) will be excluded.
• • Samples with too scarce material jeopardizing routine gold-standard diagnosis will be excluded.
• • Bone marrow aspirates without sufficient material to assess malignant or healthy hematopoiesis.